A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
Clinical trial NCT04612673 · UNKNOWN
Trial details
- NCT number
- NCT04612673
- Sponsor
- China Medical University, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-20
- Primary completion
- 2022-06-30
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.